{"meshTagsMajor":["Practice Guidelines as Topic"],"meshTags":["Antineoplastic Combined Chemotherapy Protocols","Female","Fertility Preservation","Humans","Neoplasm Staging","Practice Guidelines as Topic","Uterine Cervical Neoplasms"],"meshMinor":["Antineoplastic Combined Chemotherapy Protocols","Female","Fertility Preservation","Humans","Neoplasm Staging","Uterine Cervical Neoplasms"],"organisms":["6755","6755","6755"],"publicationTypes":["Journal Article"],"abstract":"The NCCN Guidelines for Cervical Cancer provide interdisciplinary recommendations for treating cervical cancer. These NCCN Guidelines Insights summarize the NCCN Cervical Cancer Panel\u0027s discussion and major guideline updates from 2014 and 2015. The recommended systemic therapy options for recurrent and metastatic cervical cancer were amended upon panel review of new survival data and the FDA\u0027s approval of bevacizumab for treating late-stage cervical cancer. This article outlines relevant data and provides insight into panel decisions regarding various combination regimens. Additionally, a new section was added to provide additional guidance on key principles of evaluation and surgical staging in cervical cancer. This article highlights 2 areas of active investigation and debate from this new section: sentinel lymph node mapping and fertility-sparing treatment approaches.","title":"Cervical Cancer, Version 2.2015.","pubmedId":"25870376"}